Phyllis A Satink, MS, APRN, CS Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Accepting Medicare Assignments Practice Location: 425 Poker Hill Rd, Underhill, VT 05489 Phone: 802-373-1386 Fax: 877-852-2315 |
Mary Lang Kline, CNS,APRN Clinical Nurse Specialist - Psych/Mental Health, Child & Family Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 |
Ms. Barbara L Bonney, RNCS LIP Clinical Nurse Specialist - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 215 N Main St, White River Junction, VT 05009 Phone: 802-295-9363 Fax: 802-296-6355 |
Barbara Brooks Spear, Clinical Nurse Specialist - Gerontology Medicare: Accepting Medicare Assignments Practice Location: 289 County Rd, Windsor, VT 05089 Phone: 802-674-6711 |
Lindsay Loerch, APRN Clinical Nurse Specialist - Family Health Medicare: May Accept Medicare Assignments Practice Location: 141 Etta Frasier Dr, Windsor, VT 05089 Phone: 802-674-9400 |
Mary Donohue Moore, APRN Clinical Nurse Specialist - Oncology Medicare: Accepting Medicare Assignments Practice Location: 289 County Rd, Windsor, VT 05089 Phone: 802-674-7306 Fax: 802-674-7336 |
News Archive
Highly focused, intense doses of radiation called stereotactic ablative radiation (SABR) may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
IBA Group, a leader in advanced cancer diagnosis and therapy technologies and Royal Philips Electronics, today announced they have entered into an agreement to create state of the art patient-centric proton therapy centers.
Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.
› Verified 5 days ago